Cartalax

ID: cartalax

Aliases: CARTALAX, AED peptide, cartilage peptide bioregulator

Type: compound

Route/form: regional/research peptide-bioregulator context; no established US-approved route

Status: research_or_regional

Evidence level: preclinical

Best data tier: non-human experimental

Support scope: non-human/mechanistic, review/regulatory

Source types: preclinical, review

Linked sources: 3

Broad outcomes: Longevity / mitochondrial / redox, Muscle growth / performance / recovery

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• chondrocyte secretory phenotype
• mesenchymal stem cell chondrogenic differentiation
• cartilage aging model

Optimization domains

• joint health
• cartilage
• osteoarthritis
• aging

Research basis

• Cell-culture data provide a plausible cartilage-aging/chondrocyte mechanism.
• Fits the broader Russian short-peptide bioregulator literature.

Limits, risks, and missing evidence

• No solid human osteoarthritis outcome base found here.

Risk flags

• preclinical only
• regional bioregulator literature
• identity uncertain
• unapproved context

Linked papers, labels, and reviews

1. Peptides prevent the forming of secretory phenotype of chondrocytes associated with aging
   preclinical / pubmed_cartalax_chondrocyte_2023
   Cartalax/AED-adjacent chondrocyte aging model source; translation to osteoarthritis outcomes is unproven.
2. The influence of peptides on the chondrogenic differentiation of human mesenchymal stem cells during replicative aging
   preclinical / pubmed_cartalax_chondrogenic_differentiation_2023
   Human cell-culture differentiation context for cartilage bioregulator peptide claims.
3. Peptides and ageing
   review / pubmed_short_peptides_ageing_2002
   Broad Russian peptide-bioregulator review; useful background but low specificity for named peptide products.